1ths Citations

Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor.

J Biol Chem 268 20318-26 (1993)
Cited: 19 times
EuropePMC logo PMID: 8376390

Abstract

The structures of two hirudin-based fibrinogen recognition exosite peptide inhibitors with significantly different sequences complexed with alpha-thrombin at a site distinct from the active site (exosite) have been determined crystallographically at 2.2 and 2.3 A resolution. One is a designed synthetic peptide with some nonconventional amino acid residues (MDL-28050), and the other is a natural COOH-terminal peptide isolated from the leech Hirudinaria manillensis (hirullin P18). The structures have been refined by restrained least squares methods to R values of 0.161 and 0.155, respectively. The first stretch of each peptide, corresponding to hirudin 55-59, associates with thrombin similar to hirudin and hirugen (hirudin 53-64). Although the remaining residues of the inhibitors interact with and bind to thrombin, the binding is accomplished. through a rigid body conformational adjustment of the peptide with respect to the conformation displayed by hirudin and hirugen (40 degrees rotation about the Ile59, CA-C bond). This causes the side groups of cyclohexylalanine 64' of MDL-28050 and Ile60, of hirullin to point in the opposite direction of the all important Tyr63, ring of hirudin and hirugen but permits the residues to penetrate and interact with the 3(10) turn hydrophobic binding pocket of thrombin. Thus, the hydrophobic interaction is accomplished in a different way by virtue of the substrate conformational readjustment. The results show that the first stretch of peptide makes concerted and efficient binding interactions with thrombin, and the peptide positions of the inhibitors are fairly specific and homologous so that the stretch appears to be related to specific recognition associated with the exosite. The relative flexibility of structure and sequence of the second stretch is a display of tolerance of imprecision by thrombin in its COOH-terminal hydrophobic association with hirudin-based inhibitors.

Articles - 1ths mentioned but not cited (3)

  1. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins. Kozakov D, Grove LE, Hall DR, Bohnuud T, Mottarella SE, Luo L, Xia B, Beglov D, Vajda S. Nat Protoc 10 733-755 (2015)
  2. Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery. Hall DR, Ngan CH, Zerbe BS, Kozakov D, Vajda S. J Chem Inf Model 52 199-209 (2012)
  3. Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses. Cendron L, Trovato A, Seno F, Folli C, Alfieri B, Zanotti G, Berni R. J. Biol. Chem. 284 25832-25841 (2009)


Reviews citing this publication (6)

  1. Targeting thrombin--rational drug design from natural mechanisms. Huntington JA, Baglin TP. Trends Pharmacol. Sci. 24 589-595 (2003)
  2. Coagulation factors and their inhibitors. Stubbs MT, Bode W. Curr. Opin. Struct. Biol. 4 823-832 (1994)
  3. Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects. Ascenzi P, Amiconi G, Bode W, Bolognesi M, Coletta M, Menegatti E. Mol. Aspects Med. 16 215-313 (1995)
  4. Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. Stone SR, Tapparelli C. J. Enzym. Inhib. 9 3-15 (1995)
  5. Thrombin inhibitors from different animals. Tanaka-Azevedo AM, Morais-Zani K, Torquato RJ, Tanaka AS. J. Biomed. Biotechnol. 2010 641025 (2010)
  6. Exosite Binding in Thrombin: A Global Structural/Dynamic Overview of Complexes with Aptamers and Other Ligands. Troisi R, Balasco N, Autiero I, Vitagliano L, Sica F. Int J Mol Sci 22 10803 (2021)

Articles citing this publication (10)

  1. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Vijayalakshmi J, Padmanabhan KP, Mann KG, Tulinsky A. Protein Sci. 3 2254-2271 (1994)
  2. The molecular environment of the Na+ binding site of thrombin. Zhang E, Tulinsky A. Biophys. Chem. 63 185-200 (1997)
  3. New insights into the regulation of the blood clotting cascade derived from the X-ray crystal structure of bovine meizothrombin des F1 in complex with PPACK. Martin PD, Malkowski MG, Box J, Esmon CT, Edwards BF. Structure 5 1681-1693 (1997)
  4. From natural to synthetic multisite thrombin inhibitors. Lombardi A, De Simone G, Galdiero S, Staiano N, Nastri F, Pavone V. Biopolymers 51 19-39 (1999)
  5. Computational modelling of inhibitor binding to human thrombin. Ljungberg KB, Marelius J, Musil D, Svensson P, Norden B, Aqvist J. Eur J Pharm Sci 12 441-446 (2001)
  6. Design and evaluation of novel bivalent thrombin inhibitors based on amidinophenylalanines. Steinmetzer T, Renatus M, Künzel S, Eichinger A, Bode W, Wikström P, Hauptmann J, Stürzebecher J. Eur. J. Biochem. 265 598-605 (1999)
  7. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex. De Simone G, Lombardi A, Galdiero S, Nastri F, Della Morte R, Staiano N, Pedone C, Bolognesi M, Pavone V. Protein Sci. 7 243-253 (1998)
  8. Evidence for multiple enzyme site involvement in the modulation of thrombin activity by products of prothrombin proteolysis. Shi F, Hogg PJ, Winzor DJ, Jackson CM. Biophys. Chem. 75 187-199 (1998)
  9. Stabilization of an isolated helical capping box in solution by hydrophobic interactions: evidence from the NMR study of bioactive peptides from the C-terminus of human C5a anaphylatoxin. Ni F, Carpenter KA, Ripoll DR, Sanderson SD, Hugli TE. Biopolymers 38 31-41 (1996)
  10. High throughput protease profiling comprehensively defines active site specificity for thrombin and ADAMTS13. Kretz CA, Tomberg K, Van Esbroeck A, Yee A, Ginsburg D. Sci Rep 8 2788 (2018)


Related citations provided by authors (1)

  1. Active Site and Exosite Binding of Alpha-Thrombin. Tulinsky A, Qiu X Blood Coagul. Fibrinolysis 4 305- (1993)